Follicular LymphomaClinical Notes for Practicing Oncologists
From grading and FLIPI risk stratification through GELF-guided watch-and-wait, first-line rituximab-based chemoimmunotherapy, transformation risk, and R/R management with novel agents and CAR-T.
Annual Transformation
2-3%
Cumulative risk 15-30%
PRIMA 3-yr PFS
~74.9%
With rituximab maintenance
ZUMA-5 CAR-T ORR
~91-94%
R/R FL
POD24 5-yr OS
~50%
High-risk subgroup
How is follicular lymphoma graded, and how does FLIPI risk stratification guide the treatment conversation?
Follicular lymphoma (FL) arises from germinal centre B-cells and is graded histologically by the number of centroblasts per high-power field, which correlates with clinical behaviour.
| Grade | Centroblasts/HPF | Clinical Behaviour |
|---|---|---|
| Grade 1-2 | 0-15 | Indolent — classic FL biology, often managed with watch-and-wait if low burden |
| Grade 3A | >15, admixed centrocytes present | Still generally managed as indolent FL in most guidelines |
| Grade 3B | >15, solid sheets of centroblasts, no centrocytes | Behaves more like DLBCL — typically treated with anthracycline-based chemoimmunotherapy (R-CHOP) similar to aggressive lymphoma |
| Molecular Feature | Significance |
|---|---|
| t(14;18) BCL2/IGH translocation | Present in ~85-90% of FL; leads to BCL2 overexpression and apoptosis resistance — necessary but not sufficient for lymphomagenesis |
| m7-FLIPI | Combines FLIPI with mutational status of 7 genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, CARD11) and ECOG PS for refined risk prediction |
FLIPI (5 factors)
- Age >60 years
- Ann Arbor Stage III/IV
- Haemoglobin <120 g/L
- Elevated serum LDH
- >4 nodal areas involved
0-1 = Low; 2 = Intermediate; ≥3 = High risk
FLIPI-2 (5 factors)
- Age >60 years
- Bone marrow involvement
- Haemoglobin <120 g/L
- Elevated beta-2 microglobulin
- Longest diameter of largest node >6cm
Prospectively validated refinement, using bone marrow and node size rather than stage/nodal areas.
How FLIPI is used clinically
Viva Questions & Clinical Pearls
Q: Why is grade 3B follicular lymphoma treated differently from grades 1-3A?
A: Grade 3B FL consists of solid sheets of centroblasts without centrocytes and behaves clinically more like DLBCL, so it is managed with R-CHOP-based chemoimmunotherapy rather than the indolent-lymphoma treatment paradigm.
Q: What genetic translocation defines the majority of follicular lymphoma cases and what does it do?
A: t(14;18) involving BCL2 and IGH, present in ~85-90% of FL, leading to BCL2 overexpression and resistance to apoptosis — a necessary but not sufficient step in follicular lymphomagenesis.
Clinical Decision Support
Pair these clinical notes with our validated calculators for a complete decision workflow.
Clinical reference only. These notes are intended to support, not replace, clinical judgment. Treatment decisions should be individualised based on patient-specific factors, local protocols, and multidisciplinary team input. Always apply clinical judgment and consult local institutional guidelines where applicable.